Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience

Thrombosis Research

Volumn 134, Issue , 2014, Pages S27-S32

  Kurnik, Karin ^a   Auerswald, Günter ^b   Kreuz, Wolfhart ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

^c Hämophilie Zentrum Rhein Main HZRM   (Germany)

Author keywords

Haemophilia A; Inhibitors; Previously untreated patients; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING INHIBITOR; RECOMBINANT FACTOR VIII SQ;

BLEEDING; CHILD; CHILDHOOD DISEASE; DRUG SAFETY; EARLY INTERVENTION; ETHNIC DIFFERENCE; FAMILY HISTORY; GENE MUTATION; GENETIC RISK; GERMANY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SECONDARY PREVENTION; BLOOD;

BLOOD COAGULATION FACTOR INHIBITORS; CHILD; FACTOR VIII; GERMANY; HEMOPHILIA A; HUMANS;

EID: 84922682380     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.10.017     Document Type: Review

References (65)

1. Johnson JB. Management of haemophilia with lyophile human plasma intravenously injected. JAMA 1942;118:799.
2. Alexander B, Landwehr G. Studies of haemophilia. I. The control of haemophilia by repeated infusions of normal human plasma. JAMA 1948;3:174-9.
3. Nilsson IM, Blombäck M, Ramgren O. Haemophilia in Sweden. VI. Treatment of haemophilia A with the human antihaemophilic factor preparation (Fraction I-0). Acta Med Scand Suppl 1962;379:61-110.
4. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965(Suppl. 77):3-132.
5. Pool JG, Welton J, Creger WP. Ineffectiveness of intramuscularly injected Factor 8 concentrate in two hemophilic patients. N Engl J Med 1966;275:547-8.
6. Robinson PM, Tittley P, Smiley RK. Prophylactic therapy in classical haemophilia. A preliminary report. Can Med Assoc J 1967;97:559-61.
7. Shanbrom E, Thelin GM. Experimental prophylaxis of severe hemophilia with a factor VIII concentrate. JAMA 1969;208:1835-56.
8. van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 1969;41:206-14.
9. Hirschman RJ, Itscoitz SB, Shulman NR. Prophylactic treatment of factor VIII deficiency. Blood 1970;35:189-94.
10. Kasper CK, Dietrich SL, Rapaport SL. Haemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970;125:1004-9.
11. Nilsson IM, Blombäck M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. The Hemophiliac and His World. Proceedings of the 5th Congress of the World Federation of Hemophilia, Montreal 1968. Basel/New York: Karger; 1970. p. 111-24.
12. Ramsay DM, Parker AC. A trial of prophylactic replacement therapy in haemophilia and Christmas disease. J Clin Pathol 1973;26:243-7.
13. Morfini M, Mannucci PM, Mariani G, Panicucci F, Petrucci F, Baicchi U, et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976;16:41-7.
14. Aronstam A, Kirk PJ, McHardy J, Culver-James JW, McLellan DS, Turk P, et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977;30:65-7.
15. Nilsson IM, Berntorp E, Löfqist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
16. Aledort LM, Haschmeyer RH, Pettersson H. and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-FVIIIdeficient haemophiliacs. J Intern Med 1994;236:391-9.
17. Brackmann HH, Hofmann P, Egli JE. Current management of hemophilia including self-treatment. Proceedings of the First International Symposium on Hemophilia Treatment. Tokyo, Japan: Kyoritsu Printing's; 1980.
18. Schimpf K, Fischer B, Rothmann P. Die ambulante Dauerbehandlung der Hämophilie A. Dtsch Med Wochenschr 1976;101:141-8.
19. KreuzW, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B.When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998;4:413-7.
20. Schramm W. Experience with prophylaxis in Germany. Semin Hematol 1993;30(3 Suppl. 2):12-5.
21. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992;22:251-8.
22. Kreuz WD, Krackhardt B, Scharrer I. Elimination of factor VIII inhibitors in children by induction of immune tolerance - 10 years of experience. Blut 1989;59:290 [abstract 183].
23. Kreuz W, Escuriola Ettingshausen C, Auerswald G, Heidemann P, Kemkes-Mattes B, Schneppenheim R, et al. Immune tolerance induction (ITI) in haemophilia A - patients with inhibitors - the choice of concentrate affecting success. Haematologica 2001;86(Suppl. 4):16-22.
24. Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003;88:17-20.
25. German Medical Association. Cross-sectional Guidelines for Therapy with Blood Components and Plasma Derivatives. revised ed. Executive Committee of the German Medical Association on the recommendation of the Scientific Advisory Board; 2009.
26. Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010;149:498-507.
27. Ljung R. Second workshop of the European Paediatric Network for Haemophilia Management. 17-19 September 1998 in Vitznau/Switzerland. Haemophilia 1999;5:286-91.
28. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-13.
29. Fischer K, Astermark J, van der Bom JG, Ljung R, Berntorp E, Grobbee DE, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediatedose to a high-dose regimen. Haemophilia 2002;8:753-60.
30. Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006;4:1228-36.
31. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007;357:535-44.
32. Olivieri M, Kurnik K, Pfluger T, Bidlingmaier C. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. Haemophilia 2012;18:369-74.
33. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study). J Thromb Haemost 2011;9:700-10.
34. Yee TT, Beeton K, Griffioen A, Harrington C, Miners A, Lee CA, et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002;8:76-82.
35. Berntorp E, Astermark J, Björkman S, Blanchette VS, Fischer K, Giangrande PLF, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(Suppl. 1):1-4.
36. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haemophilia 2005;130:422-7.
37. Morado M, Villar A, Jiménez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre.Haemophilia 2005;11:79-83.
38. Gouw SC, van der BomJG, van den Berg HM. for the CANAL Study Group. Treatmentrelated risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4648-54.
39. Mancuso ME, Graca L, Auerswald G, Santagostino E. Haemophilia care in children-benefits of early prophylaxis for inhibitor prevention. Haemophilia 2009;15(Suppl. 1):8-14.
40. Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001;113:600-3.
41. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe haemophilia. Thromb Haemost 2003;89:475-9.
42. Kavakli K, Gringeri A, Bader R, Nisli G, Polat A, Aydinok Y. Inhibitor development and substitution therapy in a developing country: Turkey. Haemophilia 1998;4:104-8.
43. Knobe KE, Sjörin E, Tengborn LI, Petrini P, Ljung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr 2002;91:910-4.
44. Ragni MV, Ojeifo O, Feng J, Yan J, Hill KA, Sommer SS, et al. Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia 2009;15:1074-82.
45. Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011;17:282-7.
46. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35.
47. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006;107:46-51.
48. Chalmers EA, Brown SA, Keeling D, Liesner R, RichardsM, Stirling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007;13:149-55.
49. van der Bom JG, Gouw SC, van den Berg M. Response: Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe haemophilia. Blood 2007;110:1074-5.
50. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, et al. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med 2013;368:231-9.
51. van den Berg HM, Gouw SC, van der Bom JG. Factor VIII inhibitors in severe hemophilia A. N Engl J Med 2013;368:1457.
52. Iorio A, Skinner MW, Makris M. FVIII products and inhibitors in severe haemophilia A. N Engl J Med 2013;368:1456-7.
53. Kessler CM, Iorio A. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia 2013;19:351-4.
54. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002;8(Suppl. 2):23-9.
55. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009;35:723-34.
56. Ghosh K, Shetty S. Immune response to FVIII in haemophilia A: an overview of risk factors. Clin Rev Allergy Immunol 2009;37:58-66.
57. Petrini P. What factors should influence the dosage and the interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001;7:99-102.
58. Petrini P. How to start prophylaxis. Haemophilia 2003;9(Suppl. 1):83-5.
59. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54(1):1-13.
60. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
61. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010;16:256-62.
62. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experiences. Haemophilia 2012:e18-20.
63. Nagel K, Pai MK, Paes BA, Chan AK. Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. Blood Coagul Fibrinolysis 2013;24:23-7.
64. Kulkarni R, Soucie JM, Lusher J, Presley R, Shapiro A, Gill J, et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 2009;15:1281-90.
65. Witmer C, Presley R, Kulkarni R, Soucie J, Manno KS, Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011;152:211-6.